EE533 Resource Use and Costs Among Hospital Births with Abnormal Postpartum Uterine Bleeding or Hemorrhage in the United States

Full Text

Evaluation of the Cost Saving Potential of Introducing an Etanercept Biosimilar (SB4) for the Treatment of Approved Etanercept Indications in the Republic of Ireland

Abstract

Authors

E Psachoulia S Keady

Back to Volume 20, Issue 9

Evaluation of the Cost Saving Potential of Introducing an Etanercept Biosimilar (SB4) for the Treatment of Approved Etanercept Indications in the Republic of Ireland

Abstract

Authors

ISPOR–The Professional Society for
Health Economics and Outcomes Research

Your browser is out-of-date